CAR-T cell cancer immunotherapy gets personal
Scientists have demonstrated that personalizing CAR-T cell stimulation during manufacturing can significantly enhance the consistency and potency of the resulting CAR-T cell products. By using artificial antigen-presenting cell mimicking scaffolds (APC-ms), the team was able to fine-tune the levels of T cell stimulation to match the phenotype of T cells obtained from leukemia patients, and significantly enhanced their ex vivo and in vivo tumor-clearing abilities.
Materials provided by Wyss Institute for Biologically Inspired Engineering at Harvard. Original written by Benjamin Boettner. Note: Content may be edited for style and length.
Source link aaaaa
